Verve Therapeutics (VERV) reported Monday positive initial results from its phase 1b Heart-2 clinical trial evaluating VERVE-102, a gene editing therapy for patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease.
Among 14 participants across three dose cohorts, the therapy delivered as a single infusion showed dose-dependent decreases in low-density lipoprotein cholesterol and PCSK9 protein levels. In the 0.6 mg/kg dose group, the mean LDL-C reduction was 53%, with a maximum reduction of 69%.
The therapy was well-tolerated, with no cardiovascular events, serious treatment-related adverse events, or dose-limiting toxicities, Verve Therapeutics said.
Verve is currently enrolling participants in a 0.7 mg/kg cohort in the UK, Canada, Israel, Australia, and New Zealand, and expects to present the final data in H2. A phase 2 trial is planned to start later in 2025, pending regulatory approval.
The company's shares were up over 29% in recent premarket activity.
Price: 4.22, Change: +0.96, Percent Change: +29.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.